Nuoshen Pharmaceutical (Shanghai) Co. Ltd. has disclosed new NLRP3 inflammasome inhibitors potentially useful for the treatment of neuroinflammation, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s and Huntington’s disease.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has prepared and tested new bispecific antibody-drug conjugates (ADCs) consisting of a bispecific antibody or antigen-binding fragments targeting B7 homolog 3 (B7-H3; CD276) and delta-like protein 3 (DLL3) linked to cytotoxic drug; they are described as potentially useful for the treatment of cancer.
Alphina Therapeutics Inc. has identified new nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) inhibitors potentially useful for the treatment of autoimmune and metabolic diseases, inflammatory disorders and cancer.
Neolaia Inc. has discovered new 6,5-bicyclic compounds acting as ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors potentially useful for the treatment of cancer, neurodegeneration, fibrosis, renal, inflammatory, autoimmune, metabolic and cardiovascular disease, among others.
A joint Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent details new S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors potentially useful for the treatment of cancer.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has disclosed new compounds acting as lipid-lowering agents and gluconeogenesis inhibitors potentially useful for the treatment of metabolic diseases.
Researchers from the Centre National de la Recherche Scientifique, the Institut National de la Santé et de la Recherche Médicale, Nanyang Technological University and the University of Montpellier have patented new Mycobacterium sp. ATP synthase (F0F1 ATPase) inhibitors potentially useful for the treatment of nontuberculous mycobacterial infections.
Wuhan Createrna Science and Technology Co. Ltd. has reported new complement factor D (CFD) inhibitors potentially useful for the treatment of cardiovascular, immunological, eye, genitourinary, renal, respiratory, neurological disorders and hematological diseases.
Nutshell Therapeutics Inc. has synthesized new nitrogen-containing heteroaryl compounds acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors potentially useful for the treatment of cancer.
RSS
